Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of the efficacy and safety of escitalopram for the prevention of depressive episodes induced by peg-interferon alpha2a and ribavirin in chronic hepatitis C patients. Randomized, double blind, placebo controlled clinical trial

Trial Profile

Study of the efficacy and safety of escitalopram for the prevention of depressive episodes induced by peg-interferon alpha2a and ribavirin in chronic hepatitis C patients. Randomized, double blind, placebo controlled clinical trial

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Mar 2011

At a glance

  • Drugs Escitalopram (Primary)
  • Indications Depression
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Apr 2009 Results presented at EASL 2009.
    • 07 Mar 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top